Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The University of Chicago spinout said that it will use the money to support the commercialization of its saliva-based sequencing test for oral cancers.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.